Captrust Financial Advisors acquired a new position in shares of Becton, Dickinson and Company (NYSE:BDX) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 1,613 shares of the medical instruments supplier’s stock, valued at approximately $315,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of BDX. BlackRock Inc. increased its holdings in shares of Becton, Dickinson and by 2,427.8% during the first quarter. BlackRock Inc. now owns 16,542,028 shares of the medical instruments supplier’s stock worth $3,034,470,000 after buying an additional 15,887,611 shares in the last quarter. Los Angeles Capital Management & Equity Research Inc. increased its holdings in shares of Becton, Dickinson and by 49,944.3% during the second quarter. Los Angeles Capital Management & Equity Research Inc. now owns 863,264 shares of the medical instruments supplier’s stock worth $168,431,000 after buying an additional 861,539 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of Becton, Dickinson and by 5.3% during the first quarter. Vanguard Group Inc. now owns 15,902,168 shares of the medical instruments supplier’s stock worth $2,917,094,000 after buying an additional 796,034 shares in the last quarter. Principal Financial Group Inc. increased its holdings in shares of Becton, Dickinson and by 185.3% during the second quarter. Principal Financial Group Inc. now owns 909,235 shares of the medical instruments supplier’s stock worth $177,401,000 after buying an additional 590,494 shares in the last quarter. Finally, Point72 Asset Management L.P. acquired a new stake in shares of Becton, Dickinson and during the first quarter worth approximately $101,993,000. 87.12% of the stock is owned by institutional investors.

Shares of Becton, Dickinson and Company (NYSE BDX) opened at 196.29 on Wednesday. Becton, Dickinson and Company has a one year low of $161.29 and a one year high of $206.63. The firm has a market cap of $44.67 billion, a price-to-earnings ratio of 56.85 and a beta of 1.05. The company has a 50 day moving average of $197.12 and a 200-day moving average of $192.80.

Becton, Dickinson and (NYSE:BDX) last released its quarterly earnings data on Thursday, August 3rd. The medical instruments supplier reported $2.46 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.44 by $0.02. The business had revenue of $3.04 billion during the quarter, compared to analysts’ expectations of $3.06 billion. Becton, Dickinson and had a net margin of 6.25% and a return on equity of 22.53%. The firm’s quarterly revenue was down 5.1% compared to the same quarter last year. During the same period in the prior year, the company earned $2.35 EPS. On average, analysts expect that Becton, Dickinson and Company will post $9.46 EPS for the current year.

The business also recently disclosed a quarterly dividend, which was paid on Friday, September 29th. Investors of record on Friday, September 8th were given a dividend of $0.73 per share. This represents a $2.92 dividend on an annualized basis and a yield of 1.49%. The ex-dividend date of this dividend was Thursday, September 7th. Becton, Dickinson and’s dividend payout ratio is 83.43%.

COPYRIGHT VIOLATION NOTICE: “Captrust Financial Advisors Invests $315,000 in Becton, Dickinson and Company (BDX)” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of United States & international copyright & trademark law. The original version of this piece of content can be read at https://www.thecerbatgem.com/2017/10/11/captrust-financial-advisors-invests-315000-in-becton-dickinson-and-company-bdx.html.

Several analysts have recently weighed in on BDX shares. Raymond James Financial, Inc. raised shares of Becton, Dickinson and from an “outperform” rating to a “strong-buy” rating and dropped their price objective for the stock from $210.00 to $180.00 in a report on Friday, June 30th. Cowen and Company reaffirmed an “outperform” rating and set a $230.00 price objective (up previously from $200.00) on shares of Becton, Dickinson and in a report on Monday, July 10th. BidaskClub raised shares of Becton, Dickinson and from a “buy” rating to a “strong-buy” rating in a report on Tuesday, July 11th. Zacks Investment Research raised shares of Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $225.00 price objective for the company in a report on Monday, July 17th. Finally, Bank of America Corporation reaffirmed a “buy” rating and set a $225.00 price objective (up previously from $200.00) on shares of Becton, Dickinson and in a report on Friday, July 21st. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $200.93.

In related news, insider Gary M. Cohen sold 15,512 shares of the company’s stock in a transaction that occurred on Monday, September 11th. The shares were sold at an average price of $203.77, for a total transaction of $3,160,880.24. Following the completion of the transaction, the insider now directly owns 95,781 shares in the company, valued at approximately $19,517,294.37. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Ellen R. Strahlman sold 9,283 shares of the company’s stock in a transaction that occurred on Thursday, August 10th. The stock was sold at an average price of $198.21, for a total transaction of $1,839,983.43. Following the transaction, the insider now owns 26,638 shares of the company’s stock, valued at $5,279,917.98. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 75,904 shares of company stock valued at $15,242,688. 1.40% of the stock is owned by corporate insiders.

About Becton, Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Stock Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related stocks with our FREE daily email newsletter.